Your browser is no longer supported. Please, upgrade your browser.
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E23.23 EPS (ttm)4.57 Insider Own0.10% Shs Outstand1.77B Perf Week1.99%
Market Cap189.49B Forward P/E7.73 EPS next Y13.75 Insider Trans-24.47% Shs Float1.76B Perf Month-4.14%
Income7.32B PEG4.87 EPS next Q2.79 Inst Own69.40% Short Float0.84% Perf Quarter6.62%
Sales40.65B P/S4.66 EPS this Y17.70% Inst Trans-0.86% Short Ratio2.01 Perf Half Y12.03%
Book/sh8.63 P/B12.31 EPS next Y10.59% ROA5.80% Target Price120.48 Perf Year14.10%
Cash/sh4.46 P/C23.84 EPS next 5Y4.77% ROE192.00% 52W Range62.55 - 113.41 Perf YTD-0.82%
Dividend5.20 P/FCF25.56 EPS past 5Y21.91% ROI21.50% 52W High-4.27% Beta0.80
Dividend %4.89% Quick Ratio0.80 Sales past 5Y14.90% Gross Margin68.60% 52W Low73.57% ATR2.38
Employees47000 Current Ratio1.00 Sales Q/Q52.20% Oper. Margin26.90% RSI (14)56.87 Volatility2.08% 2.24%
OptionableYes Debt/Eq5.70 EPS Q/Q2.20% Profit Margin17.00% Rel Volume0.75 Prev Close106.27
ShortableYes LT Debt/Eq5.39 EarningsFeb 03 BMO Payout98.80% Avg Volume7.40M Price108.57
Recom2.00 SMA203.03% SMA502.07% SMA20012.12% Volume4,934,986 Change2.16%
Nov-10-20Resumed Bernstein Outperform $120
Sep-29-20Initiated Berenberg Hold $98
Jun-23-20Upgrade Atlantic Equities Neutral → Overweight $115
Jun-09-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Upgrade Argus Hold → Buy $115
May-18-20Resumed BofA/Merrill Neutral $95
May-12-20Upgrade JP Morgan Neutral → Overweight $105
May-11-20Resumed Morgan Stanley Overweight $95
Apr-20-20Upgrade RBC Capital Mkts Sector Perform → Outperform $79 → $93
Mar-23-20Downgrade Societe Generale Buy → Hold
Feb-27-20Initiated Barclays Equal Weight $97
Feb-06-20Initiated Mizuho Buy
Jan-07-20Initiated RBC Capital Mkts Sector Perform $86
Dec-26-19Reiterated Cowen Outperform $90 → $98
Sep-26-19Upgrade Citigroup Neutral → Buy $87 → $90
Aug-20-19Upgrade Piper Jaffray Neutral → Overweight $80
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
May-28-19Initiated Goldman Neutral
Apr-29-19Upgrade BMO Capital Markets Underperform → Market Perform
Feb-24-21 11:09AM  
09:31AM  
Feb-23-21 08:30AM  
07:37AM  
06:04AM  
Feb-22-21 04:38PM  
12:29PM  
08:45AM  
08:13AM  
Feb-21-21 01:11PM  
06:33AM  
05:30AM  
Feb-19-21 04:05PM  
10:42AM  
09:15AM  
08:00AM  
Feb-18-21 10:58AM  
Feb-17-21 12:06PM  
06:54AM  
06:36AM  
Feb-16-21 07:15AM  
Feb-14-21 07:45AM  
07:19AM  
Feb-12-21 02:33PM  
08:56AM  
08:00AM  
Feb-11-21 10:53AM  
07:15AM  
06:40AM  
Feb-10-21 04:42PM  
10:04AM  
08:15AM  
08:00AM  
05:40AM  
Feb-09-21 01:14PM  
12:45PM  
12:00PM  
11:40AM  
10:16AM  
07:00AM  
Feb-07-21 06:01AM  
Feb-06-21 05:36PM  
Feb-05-21 11:19AM  
05:53AM  
Feb-04-21 05:17PM  
11:45AM  
09:31AM  
04:42AM  
Feb-03-21 11:22PM  
09:31PM  
04:39PM  
12:00PM  
11:38AM  
11:13AM  
10:46AM  
09:46AM  
09:39AM  
08:55AM  
07:54AM  
07:50AM  
07:38AM  
07:31AM  
03:55AM  
Feb-02-21 06:00PM  
04:07PM  
10:12AM  
06:30AM  
Feb-01-21 09:43AM  
Jan-31-21 06:04AM  
Jan-30-21 06:35AM  
Jan-29-21 07:41PM  
10:37AM  
10:22AM  
Jan-28-21 05:45PM  
Jan-27-21 08:59AM  
Jan-26-21 05:45PM  
02:32PM  
08:45AM  
07:16AM  
07:07AM  
Jan-25-21 11:30AM  
08:30AM  
Jan-22-21 10:31AM  
Jan-20-21 05:45PM  
01:00PM  
12:15PM  
Jan-15-21 09:00AM  
Jan-14-21 05:45PM  
Jan-13-21 10:28AM  
09:11AM  
07:30AM  
06:03AM  
Jan-12-21 05:45PM  
04:05PM  
08:00AM  
06:45AM  
Jan-11-21 05:45PM  
Jan-09-21 06:10AM  
06:07AM  
01:00AM  
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Frontier Medicines, Corp.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stewart Jeffrey RyanEVP, Commercial OperationsDec 29Option Exercise51.4225,2901,300,41276,259Dec 31 01:15 PM
Stewart Jeffrey RyanEVP, Commercial OperationsDec 29Sale105.0025,2902,655,45050,969Dec 31 01:15 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerNov 27Option Exercise51.4251,9902,673,32651,990Dec 01 05:22 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerNov 27Sale105.0051,9905,458,9500Dec 01 05:22 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 20Sale99.3840,0003,975,04620,006Nov 24 05:34 PM
ALBAN CARLOSVice ChairmanNov 16Option Exercise35.88115,8304,155,980230,729Nov 18 05:04 PM
ALBAN CARLOSVice ChairmanNov 16Sale100.00115,83011,583,000114,899Nov 18 05:04 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 12Option Exercise57.12194,15411,089,858512,796Nov 12 05:54 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 12Sale97.10194,15418,851,790318,642Nov 12 05:54 PM
SALEKI-GERHARDT AZITAEVP, OperationsNov 10Sale98.0017,4261,707,74896,441Nov 12 05:56 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 09Sale95.7437,4503,585,463318,642Nov 12 05:54 PM
SALEKI-GERHARDT AZITAEVP, OperationsNov 04Sale93.614,800449,328109,067Nov 06 04:29 PM
SEVERINO MICHAELVice ChairmanNov 04Sale93.6190,6798,488,46167,281Nov 06 04:29 PM
ALBAN CARLOSVice ChairmanJul 07Sale100.0053,3255,332,555114,899Jul 08 09:19 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsMay 12Sale90.0023,0242,072,21152,760May 12 05:44 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerMay 05Sale85.0019,4451,652,8250May 07 05:01 PM
Durkin Brian LVP, ControllerMar 30Buy69.0075051,75016,844Mar 20 04:56 PM
Durkin Brian LVP, ControllerMar 20Buy67.5080054,00016,094Mar 20 04:56 PM
Durkin Brian LVP, ControllerMar 18Buy68.182,200150,00515,294Mar 20 04:56 PM
RAPP EDWARD JDirectorMar 03Buy87.872,875252,6172,875Mar 04 05:14 PM